Lisata Therapeutics, Inc. (LSTA)
1.05
+0.01
(+0.96%)
USD |
NASDAQ |
Oct 21, 16:00
1.05
0.00 (0.00%)
After-Hours: 18:15
Lisata Therapeutics Net Income (Quarterly) : -2.929M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.929M |
| March 31, 2026 | -4.489M |
| December 31, 2025 | -2.954M |
| September 30, 2025 | -4.249M |
| June 30, 2025 | -4.659M |
| March 31, 2025 | -4.724M |
| December 31, 2024 | -4.61M |
| September 30, 2024 | -4.93M |
| June 30, 2024 | -5.044M |
| March 31, 2024 | -5.401M |
| December 31, 2023 | -5.365M |
| September 30, 2023 | -5.261M |
| June 30, 2023 | -4.027M |
| March 31, 2023 | -6.187M |
| December 31, 2022 | -5.99M |
| September 30, 2022 | -37.38M |
| June 30, 2022 | -6.626M |
| March 31, 2022 | -4.226M |
| December 31, 2021 | -6.794M |
| September 30, 2021 | -6.927M |
| June 30, 2021 | -5.682M |
| March 31, 2021 | -8.063M |
| December 31, 2020 | -5.432M |
| September 30, 2020 | -5.325M |
| June 30, 2020 | 6.602M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.986M |
| December 31, 2019 | -4.953M |
| September 30, 2019 | -4.897M |
| June 30, 2019 | -5.137M |
| March 31, 2019 | -4.365M |
| December 31, 2018 | -3.556M |
| September 30, 2018 | -3.549M |
| June 30, 2018 | -4.077M |
| March 31, 2018 | -4.984M |
| December 31, 2017 | -3.965M |
| September 30, 2017 | -3.548M |
| June 30, 2017 | -2.022M |
| March 31, 2017 | -6.636M |
| December 31, 2016 | -5.666M |
| September 30, 2016 | -6.091M |
| June 30, 2016 | -7.733M |
| March 31, 2016 | -12.05M |
| December 31, 2015 | -33.23M |
| September 30, 2015 | -11.39M |
| June 30, 2015 | -17.16M |
| March 31, 2015 | -19.23M |
| December 31, 2014 | -11.69M |
| September 30, 2014 | -17.18M |
| June 30, 2014 | -12.77M |
| March 31, 2014 | -13.83M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 2.929M |
| EPS Diluted (Quarterly) | -0.3217 |
| Enterprise Value | -1.213M |
| Earnings Yield | -156.3% |
| Normalized Earnings Yield | -156.27 |